Abstract
Combinations containing inhaled corticosteroids may reduce mortality in patients with COPD
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Vestbo reports personal fees from GlaxoSmithKline, personal fees from Chiesi Pharmaceuticals, personal fees from Boehringer-Ingelheim, personal fees from Novartis, personal fees from AstraZeneca, outside the submitted work.
Conflict of interest: Dr. Fabbri reports grants, personal fees and non-financial support from
Conflict of interest: Dr. Papi reports grants and personal fees from Chiesi Pharmaceuticals, during the conduct of the study; grants, personal fees, non-financial support and other from Chiesi, grants, personal fees, non-financial support and other from Astrazeneca, grants, personal fees, non-financial support and other from GlaxoSmithKline, grants, personal fees, non-financial support and other from Boehringer Ingelheim, personal fees and non-financial support from Menarini, personal fees and non-financial support from Novartis, personal fees and non-financial support from Zambon, grants, personal fees, non-financial support and other from Pfizer, grants, personal fees, non-financial support and other from Mundipharma, grants, personal fees, non-financial support and other from TEVA, outside the submitted work.
Conflict of interest: Dr. Petruzzelli has nothing to disclose.
Conflict of interest: Dr. Scuri reports and Chiesi Farmaceutici full-time amployee.
Conflict of interest: A. Guasconi is an employee of Chiesi Farmaceutici S.p.A.
Conflict of interest: Dr. Vezzoli reports and Employed by Chiesi Farmaceutici SpA, the sponsor of the studies.
Conflict of interest: Dr. Singh reports personal fees from Chiesi, during the conduct of the study; personal fees from Apellis, grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingleheim, grants and personal fees from Chiesi, personal fees from Cipla, personal fees from Genentech, grants and personal fees from GlaxoSmithKline, grants and personal fees from Glenmark, grants and personal fees from Menarini, grants and personal fees from Merck, grants and personal fees from Mundipharma, grants and personal fees from Novartis, personal fees from Peptinnovate, grants and personal fees from Pfizer, grants and personal fees from Pulmatrix, personal fees from Skyepharma, grants and personal fees from Teva, grants and personal fees from Therevance, grants and personal fees from Verona, outside the submitted work.
This is a PDF-only article. Please click on the PDF link above to read it.
- Copyright ©ERS 2018